Syndesis Health
19.9.2023 15:14:18 CEST | ACCESS Newswire | Press release
NEW YORK, NY / ACCESSWIRE / September 19, 2023 / InSyBio, a leading biotechnology company that has developed a suite of advanced AI tools for biomarker discovery in clinical and multi-omics data, has announced a strategic partnership with Syndesis Health, a leader in global real-world evidence. The partnership aims to leverage the clinical and genomic data on Syntium, Syndesis' data platform of global healthcare data, to accelerate research and development in several therapeutic areas, including cardiovascular health, oncology, and rare diseases.
The importance of biomarkers
Biomarkers are body characteristics that can be measured, such as the biological molecules found in bodily fluids or tissues, including DNA, antibodies, proteins, or other smaller molecules. They are necessary to predict the effectiveness of drugs and patient outcomes; however, biomarker discovery is a very complex and costly process that often results in poor or inaccurate outcomes due to the use of disparate tools and datasets, and the high complexity of high-throughput -omics data.
InSyBio's platform simplifies and accelerates the process of biomarker discovery by providing a single, highly accurate, and effective processing pipeline that uses machine learning to analyze biodata. Syntium's longitudinal datasets, which include clinical, genomic, and other data, are ideal for applying InSyBio's suite of tools in biomarker discovery. Combining Syntium data with InSyBio's platform will create a unique opportunity for biopharma and diagnostic companies to uncover breakthrough discoveries with the potential to vastly improve global patient outcomes.
"Precision medicine is still in its infancy and many patients are misdiagnosed or do not get the most beneficial treatment for them. The wealth of Syntium's data sets when harnessed by our automatic AI-driven technology holds the potential to upend the medical field practices, and highly impact overall healthcare quality at national and international levels. We are looking forward to working with the innovative team of Syndesis Health," said Labros Digonis, InSyBio CEO.
"We are incredibly excited to embark on this partnership with InSyBio to enable biomarker discovery for cutting-edge healthcare innovation," said Josh Sutton, Syndesis Health CEO. "Together we seek to raise the bar for global health research and innovation in service of patients worldwide."
About Syndesis Health
Syndesis Health is the data and technology catalyst to a multi-continent network of healthcare and life sciences organizations. Its primary aim is to enhance global health outcomes and equity through its secure data platform, Syntium, and the Syndesis Health Network, a member community promoting research collaboration, information sharing, and access to common tools.
About InSyBio
InSyBio is an international pioneer biotechnology company revolutionizing the medical field through targeted biomarker discovery, highly accurate predictive analytics and the development of personalization tests for drugs. Its solutions provide the R&D departments of Pharma and Research Institutes with the means to meet their most challenging research and innovation goals. This is done through a sophisticated, software-as-a-service, machine learning platform, which comprehensively integrates multi-omics and clinical data, thus reducing the number of samples and additional validation experiments needed.
Contact Information
Leah Patterson
Chief Marketing Officer
leah.patterson@syndesis.com
+1.646.274.1420
SOURCE: Syndesis Health
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/785152/syndesis-health-and-insybio-partner-in-predictive-modelling-and-biomarker-discovery
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Hydrosat and Kazakhstan Gharysh Sapary Sign Agreement to Advance Satellite-Based Water Intelligence Across Kazakhstan and Central Asia25.6.2026 17:00:00 CEST | Press release
BRUSSELS, BE / ACCESS Newswire / June 25, 2026 / Hydrosat, the leading provider of thermal infrared satellite data and AI-powered analytics, and JSC "NC "Kazakhstan Gharysh Sapary" (JSC "NC "KGS"), Kazakhstan's national space company, announced the signing of a Joint Activity Agreement during a ceremony held in Brussels on 23 June 2026. The agreement establishes the framework for a national-scale program to digitize water resources management using satellite-based thermal analytics and AI, with the potential to expand across Central Asia. The agreement was signed as part of the state visit of the Head of State of the Republic of Kazakhstan to Belgium. During the visit, a number of strategic agreements were concluded to advance artificial intelligence, science, digital infrastructure, and space technologies, creating new opportunities for investment, joint research, technology deployment, and international cooperation. Representing Kazakhstan at the signing ceremonies were Deputy Prime
GA-ASI Adapts Ground Control Station to Fly MQ-9B25.6.2026 16:00:00 CEST | Press release
World Leader in UAS Invests in Upgrades That Ease MQ-9B Procurement SAN DIEGO, CA / ACCESS Newswire / June 25, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) is working to adapt its Block 30 Ground Control Stations (GCS) to fly the company's newer model MQ-9B SkyGuardian® and SeaGuardian® Remotely Piloted Aircraft. When these upgrades are complete, they will enable current users of the Block 30 system, originally designed to fly the MQ-9A Reaper®, to keep that equipment and use it to operate the more capable aircraft. Current users include the U.S. Air Force, U.S. Marine Corps, the Italian Air Force, the French Air Force, the United Arab Emirates Armed Forces, the Spanish Air Force, and the Royal Netherlands Air Force. GA-ASI developed the MQ-9B through its own internal research and development. The upgraded new aircraft required a new and more powerful GCS. The ongoing work with the Block 30 GCS now means that prospective users with existing stocks of equipment wouldn't ne
TIS Warns that Companies are Underprepared for Impact of ISO 20022 Financial Transaction Standard25.6.2026 15:30:00 CEST | Press release
Treasury Intelligence Solutions (TIS) reports that payment disruption is now reaching corporates as banks enforce stricter data standards under the new standard for transaction messaging, and critical gaps are appearing. BERLIN, DE / ACCESS Newswire / June 25, 2026 / TIS today announced a call to action for corporate treasury, finance, and IT teams: ISO 20022 is no longer a bank-only issue, and companies that treat it as simply a messaging upgrade may face payment delays, rejected transactions, higher manual intervention, and reconciliation problems. TIS is the creator of an award-winning cloud-based platform for managing global cash flow, liquidity, and payments. Hundreds of worldwide clients rely on the TIS platform for $80 billion in daily cash management and $2.7 trillion in annual transaction volume. The TIS call to action stems from the SWIFT global financial communication network's steps to phase in ISO 20022 as the sole standard for interbank payment instructions. The new stand
Envision Pharma Group Promotes Jennifer Lospinoso to President, Riparian25.6.2026 15:00:00 CEST | Press release
FAIRFIELD, CT / ACCESS Newswire / June 25, 2026 / Envision Pharma Group (Envision) has appointed Jennifer (Jenn) Lospinoso as President of Riparian, its business unit focused on pricing, access, and value optimization for pharmaceutical and biotech companies. "Jenn's promotion reflects her exceptional leadership, deep industry expertise, and unwavering commitment to clients," said Tom Langan, CEO of Envision. "Riparian represents a significant growth opportunity for Envision, and I'm confident that Jenn and her team will drive the innovation and excellence that sets us apart and delivers for our clients." Lospinoso came to Envision as part of the 2022 acquisition of Riparian, where she served as a key leader. Jenn has built a reputation as a trusted advisor to some of the industry's leading pharmaceutical companies, guiding manufacturers through commercial strategy implementation and navigating statutory and regulatory changes across government programs, including the development of pr
Pacific Avenue Capital Partners Announces Investment Committee Appointment, New AI Initiative, and Team Expansion25.6.2026 15:00:00 CEST | Press release
LOS ANGELES, CA / ACCESS Newswire / June 25, 2026 / Pacific Avenue Capital Partners ("Pacific Avenue"), a global private equity firm focused on corporate carve-outs and other complex transactions in the middle market, today announced the appointments of Jonathan Sinnott to the Investment Committee, the establishment of a dedicated artificial intelligence team led by Al Rahrooh and supported by Ahsan Hashmi and Alejandro Urrea, and the addition of Tyler Woodhouse, Adolfo Guerra, and Francisco Lima across portfolio operations and compliance, along with a new investment team member, Saiesha Sharma, as an associate. "We remain committed to building the best private equity firm to work at in Los Angeles. Jonathan's appointment to the Investment Committee is a well-deserved recognition of his contributions and I look forward to his continued impact in this expanded role. Additionally, the establishment of our dedicated AI team is a critical initiative for the firm, and one we believe will cr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom